Casdin Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Casdin Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-650,000	Closed	-$6.08M	–	36
2025 Q2	$6.08M	Buy	650,000 +15,000	+2%	+$165K	0.55%	20
2025 Q1	$7.8M	Buy	635,000 +160,000	+34%	+$2.26M	0.64%	25
2024 Q4	$6.28M	Hold	475,000	–	–	0.42%	27
2024 Q3	$9.14M	Buy	475,000 +325,000	+217%	+$6.71M	0.61%	24
2024 Q2	$3.08M	Hold	150,000	–	–	0.24%	28
2024 Q1	$3.57M	Hold	150,000	–	–	0.27%	31
2023 Q4	$3.24M	Buy	+150,000	New	+$2.31M	0.32%	31
2021 Q4	–	Sell	-1,200,000	Closed	-$22.9M	–	56
2021 Q3	$22.9M	Hold	1,200,000	–	–	0.57%	37
2021 Q2	$20.6M	Buy	1,200,000 +200,000	+20%	+$3.66M	0.52%	36
2021 Q1	$22.4M	Buy	1,000,000 +550,000	+122%	+$12.4M	0.67%	31
2020 Q4	$10M	Buy	+450,000	New	+$9.33M	0.3%	41

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Casdin Capital's SNDX Position: Q3 2025 in Review

Casdin Capital sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 650,000 shares — an estimated $6.08M sold.

Casdin Capital first reported a position in SNDX in Q4 2020 and held it in 11 quarters. The position peaked at $22.9M in Q3 2021. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Casdin Capital reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Casdin Capital sold 650,000 Syndax Pharmaceuticals shares in Q3 2025, an estimated $6.08M.
Casdin Capital first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 11 quarters.
Casdin Capital's Syndax Pharmaceuticals position peaked at $22.9M in Q3 2021.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.